Wall Street Zen Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Buy

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Sunday.

A number of other research firms have also weighed in on SUPN. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Craig Hallum set a $65.00 target price on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Stifel Nicolaus increased their target price on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. Finally, Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $62.17.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN opened at $54.17 on Friday. The stock has a market cap of $3.12 billion, a PE ratio of -79.66, a price-to-earnings-growth ratio of 1.67 and a beta of 0.70. Supernus Pharmaceuticals has a fifty-two week low of $29.16 and a fifty-two week high of $59.68. The firm’s 50-day simple moving average is $51.05 and its two-hundred day simple moving average is $48.90.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 710 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $44.44, for a total value of $31,552.40. Following the completion of the transaction, the vice president owned 14,508 shares of the company’s stock, valued at approximately $644,735.52. The trade was a 4.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Frank Mottola sold 20,000 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the transaction, the senior vice president owned 15,496 shares in the company, valued at $781,153.36. This represents a 56.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 43,972 shares of company stock worth $2,270,833 over the last three months. Company insiders own 8.80% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

A number of large investors have recently made changes to their positions in SUPN. Hantz Financial Services Inc. increased its stake in shares of Supernus Pharmaceuticals by 81.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 281 shares in the last quarter. Torren Management LLC bought a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $49,000. USA Financial Formulas bought a new stake in Supernus Pharmaceuticals during the third quarter valued at about $50,000. Smartleaf Asset Management LLC increased its position in Supernus Pharmaceuticals by 30.8% in the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 268 shares in the last quarter. Finally, Global Retirement Partners LLC raised its stake in shares of Supernus Pharmaceuticals by 532.4% in the fourth quarter. Global Retirement Partners LLC now owns 1,404 shares of the specialty pharmaceutical company’s stock worth $70,000 after buying an additional 1,182 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.